Clinical Research Directory
Browse clinical research sites, groups, and studies.
TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients
Sponsor: Chiesi Poland Sp. z o.o.
Summary
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.
Official title: TriMaximize: A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2024-08
Completion Date
2025-08-01
Last Updated
2024-08-23
Healthy Volunteers
No
Conditions
Interventions
Trimbow
Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
Locations (1)
Indywidualna Specjalistyczna Praktyka Lekarska
Tarnowskie Góry, Poland